Fra Virogates:
ViroGates announces a new routine customer in Spain using suPARnostic® TurbiLatex for suPAR guided anakinra treatment of patients with COVID-19 disease
27.1.2022 23:08:58 CET | ViroGates | Company Announcement
COMPANY ANNOUNCEMENT – No. 01-2022 – 27 January 2022
BIRKERØD, DENMARK – ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces that Hospital Universitario y Politécnico de La Fe (La Fe) has started using suPARnostic® in clinical routine to guide anakinra treatment in adult COVID-19 patients.
La Fe is a reference hospital with an uptake population of approximately 300,000 people and 1,000 beds located in Valencia, Spain. La Fe is the first hospital in Spain that has implemented the use of suPARnostic® guided anakinra treatment. In addition, it is the first hospital in Spain to implement suPARnostic® TurbiLatex in routine use on the Abbott Alinity clinical chemistry analyzer in its central laboratory.
The European Medicines Agency officially approved using suPAR-guided anakinra treatment in adult COVID-19 patients in December 2021 based on the SAVE-MORE study published in Nature Medicine.
Doctor Laíz, head of the laboratory at La Fe, says: “We have high expectations for suPAR because we hope that suPAR will help us in the fight against Covid. We are very proud to be the first hospital in Spain to have suPAR in an Alinity.”
Jakob Knudsen, CEO of ViroGates, says: ”We are proud to be a player in the continued battle against COVID-19. We are committed to assisting in identifying COVID-19 patients with challenged immune systems who can benefit from an early anakinra intervention. We are also happy to see that the SAVE-MORE study increasingly is translated into clinical practice to the benefit of patients.”